recombinant human light Search Results


94
TargetMol tfs target
Tfs Target, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/tfs target/product/TargetMol
Average 94 stars, based on 1 article reviews
tfs target - by Bioz Stars, 2026-05
94/100 stars
  Buy from Supplier

94
R&D Systems 01 r d systems
01 R D Systems, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/01 r d systems/product/R&D Systems
Average 94 stars, based on 1 article reviews
01 r d systems - by Bioz Stars, 2026-05
94/100 stars
  Buy from Supplier

94
Boster Bio lc3 primary antibody
3D compression promotes autophagy of PDLCs. ( A ) qRT-PCR analysis for quantification of ATG7 expression at the indicated time points. ( B ) qRT-PCR analysis for quantification of Beclin1 expression at the indicated time points. ( C ) Representative immunofluorescence images of <t>LC3</t> staining at different time points. Scale bar: 100 μm. ( D ) Ratio of LC3-II/LC3-I quantified at different time points. ( E ) Immunoblotting analysis of P62 protein levels over time. ( F ) Densitometric quantification of P62 normalized to GAPDH. For ( A , B , D , F ), **, ***, ****, and ns indicate p < 0.01, p < 0.001, p < 0.0001 and no significant difference by one-way ANOVA, respectively. Shown as the mean ± SD.
Lc3 Primary Antibody, supplied by Boster Bio, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/lc3 primary antibody/product/Boster Bio
Average 94 stars, based on 1 article reviews
lc3 primary antibody - by Bioz Stars, 2026-05
94/100 stars
  Buy from Supplier

94
R&D Systems human light tnfsf14
3D compression promotes autophagy of PDLCs. ( A ) qRT-PCR analysis for quantification of ATG7 expression at the indicated time points. ( B ) qRT-PCR analysis for quantification of Beclin1 expression at the indicated time points. ( C ) Representative immunofluorescence images of <t>LC3</t> staining at different time points. Scale bar: 100 μm. ( D ) Ratio of LC3-II/LC3-I quantified at different time points. ( E ) Immunoblotting analysis of P62 protein levels over time. ( F ) Densitometric quantification of P62 normalized to GAPDH. For ( A , B , D , F ), **, ***, ****, and ns indicate p < 0.01, p < 0.001, p < 0.0001 and no significant difference by one-way ANOVA, respectively. Shown as the mean ± SD.
Human Light Tnfsf14, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human light tnfsf14/product/R&D Systems
Average 94 stars, based on 1 article reviews
human light tnfsf14 - by Bioz Stars, 2026-05
94/100 stars
  Buy from Supplier

92
R&D Systems human light protein
3D compression promotes autophagy of PDLCs. ( A ) qRT-PCR analysis for quantification of ATG7 expression at the indicated time points. ( B ) qRT-PCR analysis for quantification of Beclin1 expression at the indicated time points. ( C ) Representative immunofluorescence images of <t>LC3</t> staining at different time points. Scale bar: 100 μm. ( D ) Ratio of LC3-II/LC3-I quantified at different time points. ( E ) Immunoblotting analysis of P62 protein levels over time. ( F ) Densitometric quantification of P62 normalized to GAPDH. For ( A , B , D , F ), **, ***, ****, and ns indicate p < 0.01, p < 0.001, p < 0.0001 and no significant difference by one-way ANOVA, respectively. Shown as the mean ± SD.
Human Light Protein, supplied by R&D Systems, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human light protein/product/R&D Systems
Average 92 stars, based on 1 article reviews
human light protein - by Bioz Stars, 2026-05
92/100 stars
  Buy from Supplier

91
Novus Biologicals human kappa light chain
Fig. 1. Serum fractions B11 and C3 inhibit IT4var19 IE binding to brain endothelial cells. (A) Chromatographic fractionation of serum by size exclusion chromatography. IgG-depleted serum was run on a Superdex 200 Increase 10/300 GL column. Protein fractions were eluted using a linear gradient and the absorbance (mAbs) monitored at 280 nm. The arrows show the binding inhibitory fractions B11 and C3. (B) Binding of IT4var19 IEs to HBEC-5i in binding medium with 10% human serum, IgG-depleted human serum, or serum fractions (A6-C6). A no-serum control was included. Each data point is from two independent experiments done in duplicate, and the mean and SEM are shown for each fraction. Fractions B11 and C3 inhibited the binding the most. These fractions were run on MS/MS, and the components were run to determine their effect on binding as shown in C to identify potential inhibitors for binding. (C) Binding of IT4var19 IEs to HBEC-5i in binding medium with proteins identified by MS/MS in the serum inhibitory B11 and C3 fractions (attractin, C1s, C4b, factor <t>H,</t> <t>IgD,</t> ITIH1, ITIH2, and <t>kappa</t> light chain). Data are mean ± SEM, and each data point is from an independent experiment. **P < 0.01; ***P < 0.001.
Human Kappa Light Chain, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human kappa light chain/product/Novus Biologicals
Average 91 stars, based on 1 article reviews
human kappa light chain - by Bioz Stars, 2026-05
91/100 stars
  Buy from Supplier

94
R&D Systems human light
Fig. 1. Serum fractions B11 and C3 inhibit IT4var19 IE binding to brain endothelial cells. (A) Chromatographic fractionation of serum by size exclusion chromatography. IgG-depleted serum was run on a Superdex 200 Increase 10/300 GL column. Protein fractions were eluted using a linear gradient and the absorbance (mAbs) monitored at 280 nm. The arrows show the binding inhibitory fractions B11 and C3. (B) Binding of IT4var19 IEs to HBEC-5i in binding medium with 10% human serum, IgG-depleted human serum, or serum fractions (A6-C6). A no-serum control was included. Each data point is from two independent experiments done in duplicate, and the mean and SEM are shown for each fraction. Fractions B11 and C3 inhibited the binding the most. These fractions were run on MS/MS, and the components were run to determine their effect on binding as shown in C to identify potential inhibitors for binding. (C) Binding of IT4var19 IEs to HBEC-5i in binding medium with proteins identified by MS/MS in the serum inhibitory B11 and C3 fractions (attractin, C1s, C4b, factor <t>H,</t> <t>IgD,</t> ITIH1, ITIH2, and <t>kappa</t> light chain). Data are mean ± SEM, and each data point is from an independent experiment. **P < 0.01; ***P < 0.001.
Human Light, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human light/product/R&D Systems
Average 94 stars, based on 1 article reviews
human light - by Bioz Stars, 2026-05
94/100 stars
  Buy from Supplier

90
Boster Bio bbel mac387 polyclonal
Fig. 1. Serum fractions B11 and C3 inhibit IT4var19 IE binding to brain endothelial cells. (A) Chromatographic fractionation of serum by size exclusion chromatography. IgG-depleted serum was run on a Superdex 200 Increase 10/300 GL column. Protein fractions were eluted using a linear gradient and the absorbance (mAbs) monitored at 280 nm. The arrows show the binding inhibitory fractions B11 and C3. (B) Binding of IT4var19 IEs to HBEC-5i in binding medium with 10% human serum, IgG-depleted human serum, or serum fractions (A6-C6). A no-serum control was included. Each data point is from two independent experiments done in duplicate, and the mean and SEM are shown for each fraction. Fractions B11 and C3 inhibited the binding the most. These fractions were run on MS/MS, and the components were run to determine their effect on binding as shown in C to identify potential inhibitors for binding. (C) Binding of IT4var19 IEs to HBEC-5i in binding medium with proteins identified by MS/MS in the serum inhibitory B11 and C3 fractions (attractin, C1s, C4b, factor <t>H,</t> <t>IgD,</t> ITIH1, ITIH2, and <t>kappa</t> light chain). Data are mean ± SEM, and each data point is from an independent experiment. **P < 0.01; ***P < 0.001.
Bbel Mac387 Polyclonal, supplied by Boster Bio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/bbel mac387 polyclonal/product/Boster Bio
Average 90 stars, based on 1 article reviews
bbel mac387 polyclonal - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

93
Boster Bio collagen ii
Fig. 1. Serum fractions B11 and C3 inhibit IT4var19 IE binding to brain endothelial cells. (A) Chromatographic fractionation of serum by size exclusion chromatography. IgG-depleted serum was run on a Superdex 200 Increase 10/300 GL column. Protein fractions were eluted using a linear gradient and the absorbance (mAbs) monitored at 280 nm. The arrows show the binding inhibitory fractions B11 and C3. (B) Binding of IT4var19 IEs to HBEC-5i in binding medium with 10% human serum, IgG-depleted human serum, or serum fractions (A6-C6). A no-serum control was included. Each data point is from two independent experiments done in duplicate, and the mean and SEM are shown for each fraction. Fractions B11 and C3 inhibited the binding the most. These fractions were run on MS/MS, and the components were run to determine their effect on binding as shown in C to identify potential inhibitors for binding. (C) Binding of IT4var19 IEs to HBEC-5i in binding medium with proteins identified by MS/MS in the serum inhibitory B11 and C3 fractions (attractin, C1s, C4b, factor <t>H,</t> <t>IgD,</t> ITIH1, ITIH2, and <t>kappa</t> light chain). Data are mean ± SEM, and each data point is from an independent experiment. **P < 0.01; ***P < 0.001.
Collagen Ii, supplied by Boster Bio, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/collagen ii/product/Boster Bio
Average 93 stars, based on 1 article reviews
collagen ii - by Bioz Stars, 2026-05
93/100 stars
  Buy from Supplier

93
Cusabio recombinant human neurofilament light polypeptide nefl
Fig. 1. Serum fractions B11 and C3 inhibit IT4var19 IE binding to brain endothelial cells. (A) Chromatographic fractionation of serum by size exclusion chromatography. IgG-depleted serum was run on a Superdex 200 Increase 10/300 GL column. Protein fractions were eluted using a linear gradient and the absorbance (mAbs) monitored at 280 nm. The arrows show the binding inhibitory fractions B11 and C3. (B) Binding of IT4var19 IEs to HBEC-5i in binding medium with 10% human serum, IgG-depleted human serum, or serum fractions (A6-C6). A no-serum control was included. Each data point is from two independent experiments done in duplicate, and the mean and SEM are shown for each fraction. Fractions B11 and C3 inhibited the binding the most. These fractions were run on MS/MS, and the components were run to determine their effect on binding as shown in C to identify potential inhibitors for binding. (C) Binding of IT4var19 IEs to HBEC-5i in binding medium with proteins identified by MS/MS in the serum inhibitory B11 and C3 fractions (attractin, C1s, C4b, factor <t>H,</t> <t>IgD,</t> ITIH1, ITIH2, and <t>kappa</t> light chain). Data are mean ± SEM, and each data point is from an independent experiment. **P < 0.01; ***P < 0.001.
Recombinant Human Neurofilament Light Polypeptide Nefl, supplied by Cusabio, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant human neurofilament light polypeptide nefl/product/Cusabio
Average 93 stars, based on 1 article reviews
recombinant human neurofilament light polypeptide nefl - by Bioz Stars, 2026-05
93/100 stars
  Buy from Supplier

90
OriGene myl3 protein
Fig. 1. Serum fractions B11 and C3 inhibit IT4var19 IE binding to brain endothelial cells. (A) Chromatographic fractionation of serum by size exclusion chromatography. IgG-depleted serum was run on a Superdex 200 Increase 10/300 GL column. Protein fractions were eluted using a linear gradient and the absorbance (mAbs) monitored at 280 nm. The arrows show the binding inhibitory fractions B11 and C3. (B) Binding of IT4var19 IEs to HBEC-5i in binding medium with 10% human serum, IgG-depleted human serum, or serum fractions (A6-C6). A no-serum control was included. Each data point is from two independent experiments done in duplicate, and the mean and SEM are shown for each fraction. Fractions B11 and C3 inhibited the binding the most. These fractions were run on MS/MS, and the components were run to determine their effect on binding as shown in C to identify potential inhibitors for binding. (C) Binding of IT4var19 IEs to HBEC-5i in binding medium with proteins identified by MS/MS in the serum inhibitory B11 and C3 fractions (attractin, C1s, C4b, factor <t>H,</t> <t>IgD,</t> ITIH1, ITIH2, and <t>kappa</t> light chain). Data are mean ± SEM, and each data point is from an independent experiment. **P < 0.01; ***P < 0.001.
Myl3 Protein, supplied by OriGene, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/myl3 protein/product/OriGene
Average 90 stars, based on 1 article reviews
myl3 protein - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

92
Boster Bio human s100a8
Fig. 1. Serum fractions B11 and C3 inhibit IT4var19 IE binding to brain endothelial cells. (A) Chromatographic fractionation of serum by size exclusion chromatography. IgG-depleted serum was run on a Superdex 200 Increase 10/300 GL column. Protein fractions were eluted using a linear gradient and the absorbance (mAbs) monitored at 280 nm. The arrows show the binding inhibitory fractions B11 and C3. (B) Binding of IT4var19 IEs to HBEC-5i in binding medium with 10% human serum, IgG-depleted human serum, or serum fractions (A6-C6). A no-serum control was included. Each data point is from two independent experiments done in duplicate, and the mean and SEM are shown for each fraction. Fractions B11 and C3 inhibited the binding the most. These fractions were run on MS/MS, and the components were run to determine their effect on binding as shown in C to identify potential inhibitors for binding. (C) Binding of IT4var19 IEs to HBEC-5i in binding medium with proteins identified by MS/MS in the serum inhibitory B11 and C3 fractions (attractin, C1s, C4b, factor <t>H,</t> <t>IgD,</t> ITIH1, ITIH2, and <t>kappa</t> light chain). Data are mean ± SEM, and each data point is from an independent experiment. **P < 0.01; ***P < 0.001.
Human S100a8, supplied by Boster Bio, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human s100a8/product/Boster Bio
Average 92 stars, based on 1 article reviews
human s100a8 - by Bioz Stars, 2026-05
92/100 stars
  Buy from Supplier

Image Search Results


3D compression promotes autophagy of PDLCs. ( A ) qRT-PCR analysis for quantification of ATG7 expression at the indicated time points. ( B ) qRT-PCR analysis for quantification of Beclin1 expression at the indicated time points. ( C ) Representative immunofluorescence images of LC3 staining at different time points. Scale bar: 100 μm. ( D ) Ratio of LC3-II/LC3-I quantified at different time points. ( E ) Immunoblotting analysis of P62 protein levels over time. ( F ) Densitometric quantification of P62 normalized to GAPDH. For ( A , B , D , F ), **, ***, ****, and ns indicate p < 0.01, p < 0.001, p < 0.0001 and no significant difference by one-way ANOVA, respectively. Shown as the mean ± SD.

Journal: Gels

Article Title: A 3D Collagen–Alginate Hydrogel Model for Mechanoregulation of Autophagy in Periodontal Ligament Cells

doi: 10.3390/gels12010091

Figure Lengend Snippet: 3D compression promotes autophagy of PDLCs. ( A ) qRT-PCR analysis for quantification of ATG7 expression at the indicated time points. ( B ) qRT-PCR analysis for quantification of Beclin1 expression at the indicated time points. ( C ) Representative immunofluorescence images of LC3 staining at different time points. Scale bar: 100 μm. ( D ) Ratio of LC3-II/LC3-I quantified at different time points. ( E ) Immunoblotting analysis of P62 protein levels over time. ( F ) Densitometric quantification of P62 normalized to GAPDH. For ( A , B , D , F ), **, ***, ****, and ns indicate p < 0.01, p < 0.001, p < 0.0001 and no significant difference by one-way ANOVA, respectively. Shown as the mean ± SD.

Article Snippet: Samples were incubated with LC3 primary antibody (1:200) overnight at 4 °C, followed by secondary antibody and DAPI staining (Boster).

Techniques: Quantitative RT-PCR, Expressing, Immunofluorescence, Staining, Western Blot

AKT-mTOR signaling links compression to autophagy in PDLCs. Compression is transmitted through AKT-mTOR signaling. Modulation of this pathway by the AKT activator SC79 and the mTOR pathway modulator 3BDO alters autophagy-related gene expression. Changes in Beclin1, P62, ATG7, ATG5 and LC3-II reflect the formation of autolysosomes and the overall level of autophagic activity in periodontal ligament cells under compression. The light red arrows indicate the increase in the levels of AKT and mTOR.

Journal: Gels

Article Title: A 3D Collagen–Alginate Hydrogel Model for Mechanoregulation of Autophagy in Periodontal Ligament Cells

doi: 10.3390/gels12010091

Figure Lengend Snippet: AKT-mTOR signaling links compression to autophagy in PDLCs. Compression is transmitted through AKT-mTOR signaling. Modulation of this pathway by the AKT activator SC79 and the mTOR pathway modulator 3BDO alters autophagy-related gene expression. Changes in Beclin1, P62, ATG7, ATG5 and LC3-II reflect the formation of autolysosomes and the overall level of autophagic activity in periodontal ligament cells under compression. The light red arrows indicate the increase in the levels of AKT and mTOR.

Article Snippet: Samples were incubated with LC3 primary antibody (1:200) overnight at 4 °C, followed by secondary antibody and DAPI staining (Boster).

Techniques: Gene Expression, Activity Assay

Fig. 1. Serum fractions B11 and C3 inhibit IT4var19 IE binding to brain endothelial cells. (A) Chromatographic fractionation of serum by size exclusion chromatography. IgG-depleted serum was run on a Superdex 200 Increase 10/300 GL column. Protein fractions were eluted using a linear gradient and the absorbance (mAbs) monitored at 280 nm. The arrows show the binding inhibitory fractions B11 and C3. (B) Binding of IT4var19 IEs to HBEC-5i in binding medium with 10% human serum, IgG-depleted human serum, or serum fractions (A6-C6). A no-serum control was included. Each data point is from two independent experiments done in duplicate, and the mean and SEM are shown for each fraction. Fractions B11 and C3 inhibited the binding the most. These fractions were run on MS/MS, and the components were run to determine their effect on binding as shown in C to identify potential inhibitors for binding. (C) Binding of IT4var19 IEs to HBEC-5i in binding medium with proteins identified by MS/MS in the serum inhibitory B11 and C3 fractions (attractin, C1s, C4b, factor H, IgD, ITIH1, ITIH2, and kappa light chain). Data are mean ± SEM, and each data point is from an independent experiment. **P < 0.01; ***P < 0.001.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Article Title: Complement C1s cleaves PfEMP1 at interdomain conserved sites inhibiting Plasmodium falciparum cytoadherence.

doi: 10.1073/pnas.2104166118

Figure Lengend Snippet: Fig. 1. Serum fractions B11 and C3 inhibit IT4var19 IE binding to brain endothelial cells. (A) Chromatographic fractionation of serum by size exclusion chromatography. IgG-depleted serum was run on a Superdex 200 Increase 10/300 GL column. Protein fractions were eluted using a linear gradient and the absorbance (mAbs) monitored at 280 nm. The arrows show the binding inhibitory fractions B11 and C3. (B) Binding of IT4var19 IEs to HBEC-5i in binding medium with 10% human serum, IgG-depleted human serum, or serum fractions (A6-C6). A no-serum control was included. Each data point is from two independent experiments done in duplicate, and the mean and SEM are shown for each fraction. Fractions B11 and C3 inhibited the binding the most. These fractions were run on MS/MS, and the components were run to determine their effect on binding as shown in C to identify potential inhibitors for binding. (C) Binding of IT4var19 IEs to HBEC-5i in binding medium with proteins identified by MS/MS in the serum inhibitory B11 and C3 fractions (attractin, C1s, C4b, factor H, IgD, ITIH1, ITIH2, and kappa light chain). Data are mean ± SEM, and each data point is from an independent experiment. **P < 0.01; ***P < 0.001.

Article Snippet: For binding inhibition assays, serum and serum fractions (at 10%), recombinant human attractin (7238-AT-050; Novus Biologicals), C1s (A104; Complement Technology; or 2060-SE; R&D Systems), human complement C4b (H00000721-Q01; Novus Biologicals), human complement factor H (H00003075-P03; Novus Biologicals), IgD (NB100-62667; Novus Biologicals), human kappa light chain (H00003514-P01; Novus Biologicals), human inter-alpha-trypsin inhibitor heavy chain H1 (ITIH1) (H00003697-P01; Novus Biologicals), and H2 (ITIH2) (NBP2-31750PEP; Novus Biologicals) (at physiological concentrations in serum, ∼10% of the physiological concentrations or an estimated concentration where serum levels could not be found; see SI Appendix, Table S1) were added to the parasites in DMEM binding medium immediately before coincubation with HBEC-5i.

Techniques: Binding Assay, Fractionation, Size-exclusion Chromatography, Control, Tandem Mass Spectroscopy